AnalystBook Research · Company Intelligence

STANDARD BIOTOOLS INC.

LABNasdaq

Built from STANDARD BIOTOOLS INC.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score -0.99 distress zone — historically elevated failure riskWatch
  • Earnings-manipulation signal · Beneish M -3.05 no flag raisedOK
  • Earnings quality 76/100 accruals in line with cashOK

Where the revenue comes from

Fiscal 2025, as STANDARD BIOTOOLS INC. reports it. History and quarterly detail are in the app.

  • Product$61.7M
  • Consumables$36.2M
  • Instruments$25.4M
  • Services And Other Revenue$23.7M
  • Service And Other Revenue$23.7M

Leadership changes

From STANDARD BIOTOOLS INC.'s own filings, the day they're filed.

  • Jeremy Davis · Chief Commercial Officer · departureeff. 2025-02-01
  • Alex Kim · Chief Financial Officer · appointmenteff. 2024-11-11
  • Jeffrey Black · Chief Financial Officer · departureeff. 2024-08-31

Latest filings

  • 10-Q · Quarterly report2026-08-05
  • 8-K · Company announcement2026-08-05
  • 8-K · Company announcement2026-07-28
  • 8-K · Company announcement2026-07-24
  • 8-K · Company announcement2026-06-18
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about STANDARD BIOTOOLS INC., every answer cited to the official filings🔒
  • The Intelligence Brief — added when STANDARD BIOTOOLS INC.'s brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.